Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept Plus Glucocorticoids for Non-severe ANCA-associated Glomerulonephritis
ChiCTR2600122522Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of telitacicept in microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA) and antineutrophil cytoplasmic antibodies-associated glomerulonephritis (ANCA-GN), sponsored by Peking Union Medical College Hospital. Primary endpoints: Complete remission rate and Drug side effects. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
microscopic polyangiitis (MPA)granulomatosis with polyangiitis (GPA)antineutrophil cytoplasmic antibodies-associated glomerulonephritis (ANCA-GN)
Beyond the preview
Go deeper on ChiCTR2600122522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122522.